Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1301C Trigger Study in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma
jRCTs031180006Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab, tegafur and cisplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Oct 2016; status: active, not recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs031180006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180006.